Phototherapy: The patients' point of view

Odorici, Giulia; Nuzzo, Sergio Di; Corazza, Monica; Bardazzi, Federico; Cortelazzi, Chiara; Sacchelli, Lidia; Conti, Andrea

doi:10.1111/phpp.12629

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical spectrum of response to narrowband-UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult-to-treat body region Psoriasis is a common chronic inflammatory disorder with serious quality of life impairment. 1,2 Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) are the most validated scores for accessing psoriasis severity and response to therapy. 1,3 Plaque psoriasis is the most common form of the disease.…”

Section: E T T E Rmentioning

confidence: 99%

The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region

Brazão

Alpalhão

Filipe

2023

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Section: E T T E Rmentioning

confidence: 99%

The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region

Brazão

Alpalhão

Filipe

2023

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

“…Combination therapies with the systemic drug were prescribed in line with the "Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis" in terms of dosage and frequency [78], whilst the NB-UVB was used following the "Tuscan consensus on the use of UVBnb phototherapy" [79] and the principles of diet changes in minimal erythema dose [80] and photoadaptation [81].…”

Section: Clinical Evaluationmentioning

confidence: 99%

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

et al. 2022

Self Cite

View full text Add to dashboard Cite

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

show abstract

Phototherapy: The patients' point of view

Cited by 2 publications

References 11 publications

The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region

The clinical spectrum of response to narrowband‐UVB therapy in chronic plaque psoriasis: The lower limbs are the most difficult‐to‐treat body region

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

Contact Info

Product

Resources

About